Role of the tumor suppressor ARF in macrophage polarization: Enhancement of the M2 phenotype in ARF-deficient mice

OncoImmunology

Volumn 1, Issue 8, 2012, Pages 1227-1238

  Herranz, Sandra ^a   Través, Paqui G ^b   Luque, Alfonso ^c   Hortelano, Sonsoles ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^c Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria   (Spain)

Author keywords

Alternative activation; ARF; IL 4; Macrophage; TAMs

Indexed keywords

CYCLOOXYGENASE 2; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 13; INTERLEUKIN 4;

ANIMAL CELL; ARF GENE; ARTICLE; CCL24 GENE; CCL3 GENE; CCL4 GENE; CCR3 GENE; CCR5 GENE; CONTROLLED STUDY; CXCL1 GENE; CXCL10 GENE; CXCL6 GENE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; FIZZ 1 GENE; GENE EXPRESSION; GENE FUNCTION; I16ST GENE; IMMUNE RESPONSE; MACROPHAGE; MACROPHAGE ACTIVATION; MMR GENE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UPREGULATION; YM1 GENE;

EID: 84872144499     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21207     Document Type: Article

References (28)

1. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23:549-55; PMID:12401408; http://dx.doi.org/10.1016/S1471-4906(02)02302-5.
2. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3:23-35; PMID:12511873; http://dx.doi.org/10.1038/nri978.
3. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009; 27:451-83; PMID:19105661; http://dx.doi.org/10.1146/annurev.immunol.021908.132532.
4. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci 2008; 13:453-61; PMID:17981560; http://dx.doi.org/10.2741/2692.
5. Raes G, De Baetselier P, Noël W, Beschin A, Brombacher F, Hassanzadeh Gh G. Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages. J Leukoc Biol 2002; 71:597-602; PMID:11927645.
6. Nair MG, Cochrane DW, Allen JE. Macrophages in chronic type 2 inflammation have a novel phenotype characterized by the abundant expression of Ym1 and Fizz1 that can be partly replicated in vitro. Immunol Lett 2003; 85:173-80; PMID:12527225; http://dx.doi.org/10.1016/S0165-2478(02)00225-0.
7. Través PG, López-Fontal R, Luque A, Hortelano S. The tumor suppressor ARF regulates innate immune responses in mice. J Immunol 2011; 187:6527-38; PMID:22095712; http://dx.doi.org/10.4049/jimmunol.1004070.
8. Munder M, Eichmann K, Modolell M. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol 1998; 160:5347-54; PMID:9605134.
9. Sharpless NE. INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res 2005; 576:22-38; PMID:15878778; http://dx.doi.org/10.1016/j.mrfmmm.2004.08.021.
10. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997; 91:649-59; PMID:9393858; http://dx.doi.org/10.1016/S0092-8674(00)80452-3.
11. Kamijo T, Bodner S, van de Kamp E, Randle DH, Sherr CJ. Tumor spectrum in ARF-deficient mice. Cancer Res 1999; 59:2217-22; PMID:10232611.
12. García MA, Collado M, Muñoz-Fontela C, Matheu A, Marcos-Villar L, Arroyo J, et al. Antiviral action of the tumor suppressor ARF. EMBO J 2006; 25:4284-92; PMID:16957780; http://dx.doi.org/10.1038/sj.emboj.7601302.
13. Chang CI, Liao JC, Kuo L. Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res 2001; 61:1100-6; PMID:11221839.
14. Rodríguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 2008; 222:180-91; PMID:18364002; http://dx.doi.org/10.1111/j.1600-065X.2008.00608.x.
15. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005; 65:3044-8; PMID:15833831.
16. Lepique AP, Daghastanli KR, Cuccovia IM, Villa LL. HPV16 tumor associated macrophages suppress antitumor T cell responses. Clin Cancer Res 2009; 15:4391-400; PMID:19549768; http://dx.doi.org/10.1158/1078-0432.CCR-09-0489.
17. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007; 13:721s-6s; PMID:17255300; http://dx.doi.org/10.1158/1078-0432.CCR-06-2197.
18. Liu T, Dhanasekaran SM, Jin H, Hu B, Tomlins SA, Chinnaiyan AM, et al. FIZZ1 stimulation of myofibroblast differentiation. Am J Pathol 2004; 164:1315-26; PMID:15039219; http://dx.doi.org/10.1016/S0002-9440(10)63218-X.
19. Webb DC, McKenzie AN, Foster PS. Expression of the Ym2 lectin-binding protein is dependent on interleukin (IL)-4 and IL-13 signal transduction: identification of a novel allergy-associated protein. J Biol Chem 2001; 276:41969-76; PMID:11553626; http://dx.doi.org/10.1074/jbc.M106223200.
20. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002; 2:289-300; PMID:12398893; http://dx.doi.org/10.1016/S1535-6108(02)00153-8.
21. Kawagishi H, Nakamura H, Maruyama M, Mizutani S, Sugimoto K, Takagi M, et al. ARF suppresses tumor angiogenesis through translational control of VEGFA mRNA. Cancer Res 2010; 70:4749-58; PMID:20501856; http://dx.doi.org/10.1158/0008-472.CAN-10-0368.
22. Fatyol K, Szalay AA. The p14ARF tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1alpha (HIF-1alpha) and inhibits HIF-1-mediated transcription. J Biol Chem 2001; 276:28421-9; PMID:11382768; http://dx.doi.org/10.1074/jbc.M102847200.
23. Zerrouqi A, Pyrzynska B, Febbraio M, Brat DJ, Van Meir EG. P14ARF inhibits human glioblastoma- induced angiogenesis by upregulating the expression of TIMP3. J Clin Invest 2012; 122:1283-95; PMID:22378045; http://dx.doi.org/10.1172/JCI38596.
24. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25:677-86; PMID:15530839; http://dx.doi.org/10.1016/j.it.2004.09.015.
25. Zeini M, Través PG, López-Fontal R, Pantoja C, Matheu A, Serrano M, et al. Specific contribution of p19(ARF) to nitric oxide-dependent apoptosis. J Immunol 2006; 177:3327-36; PMID:16920973.
26. Cuadrado I, Cidre F, Herranz S, Estevez-Braun A, de las Heras B, Hortelano S. Labdanolic acid methyl ester (LAME) exerts anti-inflammatory effects through inhibition of TAK-1 activation. Toxicol Appl Pharmacol 2012; 258:109-17; PMID:22036724; http://dx.doi.org/10.1016/j.taap.2011.10.013.
27. Tai SK, Chang HC, Lan KL, Lee CT, Yang CY, Chen NJ, et al. Decoy receptor 3 enhances tumor progression via induction of tumor-associated macrophages. J Immunol 2012; 188:2464-71; PMID:22287720; http://dx.doi.org/10.4049/jimmunol.1101101.
28. Través PG, López-Fontal R, Cuadrado I, Luque A, Boscá L, de Las Heras B, et al. Critical role of the death receptor pathway in the antitumoral effects induced by hispanolone derivatives. Oncogene 2012; PMID:22310289; http://dx.doi.org/10.1038/onc.2012.23.